Alector appoints Sara Kenkare-Mitra as President and Head of R&D

Alector, Inc.

Dr. Kenkare-Mitra joins from Genentech, most recently SVP of Development Sciences.
Annual base salary of $570,000; eligible for 100% bonus and $500,000 sign-on bonus.
Equity grants: 300,000 stock options (4-yr vest), 59,000 RSUs (3-yr vest), 59,000 PSUs (1-yr performance-based vest).
She will report to CEO Arnon Rosenthal and lead all immuno-neurology and oncology R&D efforts.
Effective December 15, 2021; includes standard change-in-control and severance agreement (Tier 2).

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Saraswati (Sara) Kenkare-Mitra

President and Head of Research and Development

ALEC · Alector, Inc.

Effective: 2021-12-15
Filed: December 15, 2021, 6:59 PM ET

On December 15, 2021, Alector, Inc. (“Alector”) announced the appointment of Saraswati (Sara) Kenkare-Mitra, Ph.D. as Alector’s President and Head of Research and Development.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Saraswati (Sara) Kenkare-Mitra was appointed as President and Head of Research and Development at Alector, Inc..

Action: appointed
Role: President and Head of Research and Development

Exact text from the filing

On December 15, 2021, Alector, Inc. (“Alector”) announced the appointment of Saraswati (Sara) Kenkare-Mitra, Ph.D. as Alector’s President and Head of Research and Development.

View on SEC.gov

Alector, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-21-005217

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.